vs
Apellis Pharmaceuticals, Inc.（APLS）与JFrog Ltd（FROG）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是JFrog Ltd的1.4倍（$199.9M vs $145.3M），JFrog Ltd净利率更高（-10.5% vs -29.5%，领先19.0%），JFrog Ltd同比增速更快（25.2% vs -5.9%），JFrog Ltd自由现金流更多（$49.9M vs $-14.3M），过去两年JFrog Ltd的营收复合增速更高（20.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
JFrog Ltd是全球知名的DevOps技术服务商，面向科技、金融、零售、制造等多个行业客户，提供全链路软件发布、制品管理与安全解决方案，助力企业简化云、本地及混合部署环境下的应用开发与交付流程。
APLS vs FROG — 直观对比
营收规模更大
APLS
是对方的1.4倍
$145.3M
营收增速更快
FROG
高出31.1%
-5.9%
净利率更高
FROG
高出19.0%
-29.5%
自由现金流更多
FROG
多$64.1M
$-14.3M
两年增速更快
FROG
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $145.3M |
| 净利润 | $-59.0M | $-15.2M |
| 毛利率 | — | 77.9% |
| 营业利润率 | -25.6% | -14.7% |
| 净利率 | -29.5% | -10.5% |
| 营收同比 | -5.9% | 25.2% |
| 净利润同比 | -62.2% | 34.4% |
| 每股收益（稀释后） | $-0.40 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFROG
| Q4 25 | $199.9M | $145.3M | ||
| Q3 25 | $458.6M | $136.9M | ||
| Q2 25 | $178.5M | $127.2M | ||
| Q1 25 | $166.8M | $122.4M | ||
| Q4 24 | $212.5M | $116.1M | ||
| Q3 24 | $196.8M | $109.1M | ||
| Q2 24 | $199.7M | $103.0M | ||
| Q1 24 | $172.3M | $100.3M |
净利润APLSFROG
| Q4 25 | $-59.0M | $-15.2M | ||
| Q3 25 | $215.7M | $-16.4M | ||
| Q2 25 | $-42.2M | $-21.7M | ||
| Q1 25 | $-92.2M | $-18.5M | ||
| Q4 24 | $-36.4M | $-23.2M | ||
| Q3 24 | $-57.4M | $-22.9M | ||
| Q2 24 | $-37.7M | $-14.3M | ||
| Q1 24 | $-66.4M | $-8.8M |
毛利率APLSFROG
| Q4 25 | — | 77.9% | ||
| Q3 25 | — | 77.4% | ||
| Q2 25 | — | 76.3% | ||
| Q1 25 | — | 75.3% | ||
| Q4 24 | — | 75.4% | ||
| Q3 24 | — | 75.0% | ||
| Q2 24 | — | 78.8% | ||
| Q1 24 | — | 79.5% |
营业利润率APLSFROG
| Q4 25 | -25.6% | -14.7% | ||
| Q3 25 | 48.7% | -15.8% | ||
| Q2 25 | -18.6% | -20.4% | ||
| Q1 25 | -50.0% | -18.8% | ||
| Q4 24 | -12.3% | -21.9% | ||
| Q3 24 | -24.0% | -27.4% | ||
| Q2 24 | -14.7% | -18.6% | ||
| Q1 24 | -36.0% | -16.6% |
净利率APLSFROG
| Q4 25 | -29.5% | -10.5% | ||
| Q3 25 | 47.0% | -12.0% | ||
| Q2 25 | -23.6% | -17.0% | ||
| Q1 25 | -55.3% | -15.1% | ||
| Q4 24 | -17.1% | -20.0% | ||
| Q3 24 | -29.2% | -21.0% | ||
| Q2 24 | -18.9% | -13.9% | ||
| Q1 24 | -38.5% | -8.8% |
每股收益（稀释后）APLSFROG
| Q4 25 | $-0.40 | $-0.13 | ||
| Q3 25 | $1.67 | $-0.14 | ||
| Q2 25 | $-0.33 | $-0.19 | ||
| Q1 25 | $-0.74 | $-0.16 | ||
| Q4 24 | $-0.30 | $-0.21 | ||
| Q3 24 | $-0.46 | $-0.21 | ||
| Q2 24 | $-0.30 | $-0.13 | ||
| Q1 24 | $-0.54 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $704.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $887.4M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSFROG
| Q4 25 | $466.2M | $704.4M | ||
| Q3 25 | $479.2M | $651.1M | ||
| Q2 25 | $370.0M | $611.7M | ||
| Q1 25 | $358.4M | $563.5M | ||
| Q4 24 | $411.3M | $522.0M | ||
| Q3 24 | $396.9M | $467.8M | ||
| Q2 24 | $360.1M | $591.3M | ||
| Q1 24 | $325.9M | $579.6M |
总债务APLSFROG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSFROG
| Q4 25 | $370.1M | $887.4M | ||
| Q3 25 | $401.2M | $859.4M | ||
| Q2 25 | $156.3M | $826.5M | ||
| Q1 25 | $164.2M | $800.0M | ||
| Q4 24 | $228.5M | $773.5M | ||
| Q3 24 | $237.1M | $756.2M | ||
| Q2 24 | $264.3M | $721.4M | ||
| Q1 24 | $266.7M | $707.8M |
总资产APLSFROG
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.1B | ||
| Q3 24 | $901.9M | $1.1B | ||
| Q2 24 | $904.5M | $1.0B | ||
| Q1 24 | $831.9M | $997.1M |
负债/权益比APLSFROG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $50.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $49.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 34.3% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $142.3M |
8季度趋势，按日历期对齐
经营现金流APLSFROG
| Q4 25 | $-14.2M | $50.7M | ||
| Q3 25 | $108.5M | $30.2M | ||
| Q2 25 | $4.4M | $36.1M | ||
| Q1 25 | $-53.4M | $28.8M | ||
| Q4 24 | $19.4M | $49.1M | ||
| Q3 24 | $34.1M | $27.6M | ||
| Q2 24 | $-8.3M | $16.7M | ||
| Q1 24 | $-133.0M | $17.5M |
自由现金流APLSFROG
| Q4 25 | $-14.3M | $49.9M | ||
| Q3 25 | $108.3M | $28.8M | ||
| Q2 25 | $4.4M | $35.5M | ||
| Q1 25 | $-53.4M | $28.1M | ||
| Q4 24 | $19.3M | $48.5M | ||
| Q3 24 | — | $26.7M | ||
| Q2 24 | $-8.4M | $16.0M | ||
| Q1 24 | $-133.3M | $16.6M |
自由现金流率APLSFROG
| Q4 25 | -7.1% | 34.3% | ||
| Q3 25 | 23.6% | 21.0% | ||
| Q2 25 | 2.5% | 27.9% | ||
| Q1 25 | -32.0% | 23.0% | ||
| Q4 24 | 9.1% | 41.8% | ||
| Q3 24 | — | 24.5% | ||
| Q2 24 | -4.2% | 15.5% | ||
| Q1 24 | -77.3% | 16.6% |
资本支出强度APLSFROG
| Q4 25 | 0.1% | 0.6% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.2% | 0.8% |
现金转化率APLSFROG
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FROG
暂无分部数据
